X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more
Market Cap & Net Worth: X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) has a market capitalization of $369.86 Million ($369.86 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12878 globally and #5437 in its home market, demonstrating a 1.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying X4 Pharmaceuticals Inc's stock price $4.23 by its total outstanding shares 87436688 (87.44 Million).
X4 Pharmaceuticals Inc Market Cap History: 2017 to 2026
X4 Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $6.69 Billion to $369.86 Million (-30.14% CAGR).
Index Memberships
X4 Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #350 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1262 of 3165 |
Weight: X4 Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
X4 Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how X4 Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
25.09x
X4 Pharmaceuticals Inc's market cap is 25.09 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.22 Billion | $3.50 Million | -$43.02 Million | 347.75x | N/A |
| 2019 | $935.57 Million | $3.00 Million | -$56.60 Million | 311.86x | N/A |
| 2020 | $562.22 Million | $3.00 Million | -$62.13 Million | 187.41x | N/A |
| 2024 | $64.14 Million | $2.56 Million | -$37.45 Million | 25.09x | N/A |
Competitor Companies of XFOR by Market Capitalization
Companies near X4 Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to X4 Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
X4 Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, X4 Pharmaceuticals Inc's market cap moved from $6.69 Billion to $ 369.86 Million, with a yearly change of -30.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $369.86 Million | +5.75% |
| 2025 | $349.75 Million | +445.26% |
| 2024 | $64.14 Million | -12.56% |
| 2023 | $73.36 Million | -15.51% |
| 2022 | $86.82 Million | -56.64% |
| 2021 | $200.23 Million | -64.39% |
| 2020 | $562.22 Million | -39.91% |
| 2019 | $935.57 Million | -23.13% |
| 2018 | $1.22 Billion | -81.82% |
| 2017 | $6.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of X4 Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $369.86 Million USD |
| MoneyControl | $369.86 Million USD |
| MarketWatch | $369.86 Million USD |
| marketcap.company | $369.86 Million USD |
| Reuters | $369.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.